Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: Animal models and translation to human clinical trials
Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: Animal models and translation to human clinical trials
复制标题
DOI：
10.1089/thy.2007.0406
复制
发表时间：
2008-09-01
期刊：
影响因子：
6.6
通讯作者：
Hegedus, Laszlo
中科院分区：
文献类型：
--
作者：
Banga, J. Paul;Nielsen, Claus H.;Hegedus, Laszlo
目前大多数治疗格雷夫斯病的方法基本上都是基于近 50 年前开发的治疗方案。此外，甲状腺相关眼病（TAO）和皮肤病等并发症的治疗方法完全依赖于非特异性免疫抑制的传统方法。最近开发的实验性格雷夫斯病诱导模型虽然不完整，因为它缺乏甲状腺外表现，但为研究免疫干预策略提供了机会，包括对自身免疫过程中自身反应性 B 和 T 细胞参与者的影响。这些重大进展为格雷夫斯病和 TAO 患者的治疗干预创造了新的可能性。
Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO.